Labcorp (LH): Is Its Earnings Discount Worth the Growing Investment Bill?
Labcorp Holdings Inc. (NYSE:LH) earns fees from routine and specialty medical tests and laboratory services supporting drug development. Physicians, hospitals, and pharmaceutical companies provide different sources of demand, while personalized treatments create opportunities for more sophisticated testing. Capturing that demand requires spending on equipment, technology, and capacity before the resulting cash arrives.
Insider Monkey lists the company in its 12 Best Healthcare Stocks to Buy Now. Its investment question is whether stronger profits can overcome the cash demands of expansionand justify the forward valuation.
Specialty Testing Must Earn Back the Investment
Labcorp Holdings Inc. (NYSE:LH) can spread equipment, logistics, and administrative costs across a broad testing network. Established physician relationships and insurance coverage help direct specimens into that network. Its drug-development laboratories also create opportunities as personalized treatments require specialized tests.
Second-quarter diagnostics organic growth combined 1.8% higher requisition volume with a 1.8% price-and-mix contribution. More activity and better revenue per requisition supported a company-defined non-GAAP adjusted operating margin for the group of 15.8%, up from 15.1%. This provides evidence of service scale translating into better operating economics.
Maintaining that advantage requires investment in automation, scientific capabilities and laboratory capacity. Higher personnel costs partly offset operating improvements. The network deserves valuation credit when additional testing earns more than the cost of expanding and maintaining it.
The Lower Forward Multiple Depends on Stronger Earnings
Labcorp Holdings Inc. (NYSE:LH) carries approximately 16x forward P/E and 26x trailing P/E. Trailing P/E uses past-year earnings; forward P/E uses forecast earnings. The forward valuation is defensible if laboratory productivity supports earnings growth and restores cash generation after investment.
Reported and adjusted earnings provide different starting points. Adding the latest four quarters gives approximately $12.09 in reported EPS, versus $17.49 in company-defined non-GAAP adjusted EPS. Both adjusted EPS and adjusted operating margin exclude amortization, restructuring, acquisition-related expenses, and selected process-improvement costs, among other items. Acquired-intangible amortization reduces reported profit without a corresponding current cash payment, but buying those businesses still consumes capital.
